Murine il 3

T24 and KNS62 were purchased from National Institute of Biomedical lnnovation JCRB Cell Bank, Japan. NCI-H1915, Phoenix and RL952 were purchased from ATCC. KYSE-30, CAL-12T, HCC44, HCC78 and Ba/F3 were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen), Germany. Lung cancer cell line NCI-H1915 cells were cultured in RPMI medium supplemented with 10% fetal calf serum (FCS) and 1 mM L-glutamine. KNS62, T24 and CAL12T cells were cultured in DMEM medium supplemented with 10% fetal calf serum and 1 mM L-glutamine. RL952 cells were cultured in DMEM and F12 medium (1:1) supplemented with 10% fetal calf serum, 0.005 mg/ml insulin (1:100 Opi) and 1 mM L-glutamine. KYSE30 cells were cultured in RPMI 1640 and F12 medium (1:1) supplemented with 10% fetal calf serum and 1 mM L-glutamine. Lung cancer cell lines HCC44 and HCC78 cells were cultured in RPMI medium supplemented with 10% fetal calf serum and 1 mM L-glutamine. Lung cancer cell line HCC827 cells were cultured in RPMI medium supplemented with 20% fetal calf serum and 1 mM L-glutamine. Ba/F3 cells were maintained in RPMI-1640 supplemented with 10% FCS and 0.5 ng/ml murine IL-3 (Sigma-Aldrich). For serum reduced experiments cell lines were kept in Accell serum free media (Dharmacon) supplemented with 1% FCS. For hypoxia studies cells were kept for 96 h in a 0.2% hypoxia chamber Invivo2 400 (Ruskinn).

Murine IL-3 was purchased from Sigma-Aldrich. AZD6244, MEK162 and PD0325901 were purchased from Selleck Chemical. Everolimus and AZD8055 were purchased from MedChemExpress. All inhibitors were solubilized in dimethyl sulfoxide (DMSO) at stock concentrations of 1 mM.